论文部分内容阅读
Background Intradialytic hypotension (IDH) is a global public health problem.A rising number of IDH sufferers resort to Chinese patent medicine,Shengrnai Injection (SMI) in China.The objectives of present study are to assess the effectiveness and safety of SMI as an adjunct therapy for IDH.